BIOLOGICAL THERAPY AND INFECTION IN RHEUMATOID ARTHRITIS PATIENTS: MODERN ASPECTS

• Main Authors: B. S. BELOV, M. S. NAUMTSEVA, G. M. TARASOVA, D. V. BUKHANOVA
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2016-12-01
• Series: Медицинский совет
• Subjects: rheumatoid arthritis; gene engineering biological drugs; infections; vaccination
• Online Access: https://www.med-sovet.pro/jour/article/view/1550

In the recent decades rheumatology has been witnessing the marked progress associated with introduction into clinical practice of gene engineering biological drugs. At the same time use of these drugs is associated with the increasing risk of development of infections of various nature and localization including opportunistic (invasive mycoses, pneumocystic pneumonia etc.) as well as the increased risk of reactivation of the latent infection, tuberculosis (TB), first of all. In addition to this, cases of grave infections (pneumonia, sepsis, bacterial arthritis, skin and soft tissue lesions etc.) are registered, including – with letal outcome. This review analyzes the literature data predominantly of the recent 5 years relating to frequency and localization of infections in rheumatoid arthritis patients at therapy by various GIBD. The importance of various infections (TB, pneumonias, chronic viral hepatitis, herpes-viral infections etc.) in the tactics of the specified patients follow-up is characterized. The necessity of a wider use of immunization by various vaccines (first of all, pneumococcal and anti-flu ones) of patients with autoimmune inflammatory rheumatic diseases is underlined.